Loading...
XSHE300122
Market cap9.24bUSD
Dec 24, Last price  
27.86CNY
1D
0.98%
1Q
21.39%
Jan 2017
69.16%
IPO
51.74%
Name

Chongqing Zhifei Biological Products Co Ltd

Chart & Performance

D1W1MN
XSHE:300122 chart
P/E
8.35
P/S
1.27
EPS
3.34
Div Yield, %
1.32%
Shrs. gr., 5y
-0.52%
Rev. gr., 5y
58.87%
Revenues
52.92b
+38.30%
492,428,885590,335,676604,047,459737,313,591628,740,039764,619,690780,177,947800,937,517712,738,059445,947,1521,342,568,6325,228,307,72810,587,318,31115,190,366,23130,652,415,90638,264,011,33152,917,767,029
Net income
8.07b
+7.04%
152,009,074190,051,259231,589,722256,788,078196,383,625217,943,859130,347,838148,003,991197,401,92232,520,311432,275,4001,451,366,5282,366,438,7333,301,326,83010,208,548,4527,538,999,6978,069,868,204
CFO
9.00b
+352.30%
111,659,461141,584,417210,612,67454,190,253221,247,243112,891,820221,576,180161,388,660223,448,28389,954,889203,609,676585,590,1951,366,993,8303,496,688,9408,507,591,8171,989,033,1058,996,369,981
Dividend
Aug 08, 20240.8 CNY/sh

Profile

Chongqing Zhifei Biological Products Co., Ltd. engages in the research, development, manufacture, and marketing of vaccines and biological products in China. The company was founded in 2009 and is based in Chongqing, China.
URL
http://www.zhifeishengwu.com/
IPO date
Sep 28, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
52,917,767
38.30%
38,264,011
24.83%
30,652,416
101.79%
Cost of revenue
41,651,452
28,579,251
18,101,755
Unusual Expense (Income)
NOPBT
11,266,315
9,684,761
12,550,661
NOPBT Margin
21.29%
25.31%
40.95%
Operating Taxes
1,272,425
1,179,008
1,722,506
Tax Rate
11.29%
12.17%
13.72%
NOPAT
9,993,890
8,505,752
10,828,155
Net income
8,069,868
7.04%
7,539,000
-26.15%
10,208,548
209.23%
Dividends
(889,289)
(960,000)
(800,000)
Dividend yield
0.61%
0.70%
0.27%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
2,635,483
1,794,721
569,107
Long-term debt
378,695
266,172
260,893
Deferred revenue
238,342
222,203
Other long-term liabilities
228,274
Net debt
(3,621,334)
(855,819)
(3,768,203)
Cash flow
Cash from operating activities
8,996,370
1,989,033
8,507,592
CAPEX
(1,134,172)
Cash from investing activities
(976,599)
Cash from financing activities
(4,293,867)
FCF
5,766,036
(842,517)
6,670,479
Balance
Cash
6,340,512
2,622,064
4,307,752
Long term investments
295,000
294,648
290,452
Excess cash
3,989,624
1,003,512
3,065,583
Stockholders' equity
31,458,116
24,028,248
17,449,248
Invested Capital
30,733,602
24,351,641
13,941,591
ROIC
36.29%
44.42%
91.41%
ROCE
32.39%
38.11%
73.59%
EV
Common stock shares outstanding
2,400,032
2,400,000
2,400,000
Price
61.11
7.15%
57.03
-54.23%
124.60
-15.76%
Market cap
146,665,967
7.16%
136,871,993
-54.23%
299,039,984
-15.76%
EV
143,044,633
136,016,174
295,271,781
EBITDA
11,604,700
9,999,704
12,926,508
EV/EBITDA
12.33
13.60
22.84
Interest
117,439
53,296
56,145
Interest/NOPBT
1.04%
0.55%
0.45%